{"id":38670,"date":"2017-04-20T07:15:14","date_gmt":"2017-04-20T11:15:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=38670"},"modified":"2017-04-20T04:17:40","modified_gmt":"2017-04-20T08:17:40","slug":"ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670","title":{"rendered":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Ampliphi Biosciences Corp (NYSEMKT:APHB)<\/strong> has proclaimed the positive feedback they got from the U.S. based Food and Drug Administration (FDA) on their second phase of their development plan. As a result, the company will retain its H.C. Wainwright and Co. LLC to offer the company and its directors on the way forward in reviewing the alternative strategic goals.<\/p>\n<p style=\"text-align: justify;\">The company, which provides therapies for a variety of drug-resistant bacteria infections, received encouraging results from the FDA on their detailed development proposals that they submitted earlier. The progress will now all the company to proceed with their second phase trial using Bacteriophage technology which includes a cocktail of AB-SA01 substance that would be useful in treating the notorious antibiotic-resistant <em>Staphylococcus aureus<\/em> (<em>S. aureus<\/em>) infections in patients suffering from the chronic rhinosinusitis (CRS).<\/p>\n<p style=\"text-align: justify;\">The feedback from FDA was affirmed after the Type B telephonic meeting that took place in February this year. According to FDA officials, the phage therapy that was proposed by the Ampliphi is one of the thrilling and unique approaches to curing of a wide range of multidrug-resistant organisms and believed the company is capable and committed to addressing the exceptional regulatory disputes that could arise during the stages of product development.<\/p>\n<p style=\"text-align: justify;\">The company has already reviewed the current status of its resources, internal programs, and capabilities to take up the challenge. The firm is exploring a variety of alternative strategies that could enable them to maximize the value of their shareholders. In the past two years, the company has managed to commence the world\u2019s first cGMP facility which is devoted to manufacturing high-quality phage cocktails drugs. They also produced the necessary phage materials needed for to complete phase I of the trials. These generated positive results paving way for more research into patients that do not respond well to the conventional antibiotics.<\/p>\n<p style=\"text-align: justify;\">The company will work along with the highly-experienced team from H.C. Wainwright and Co to make use of their world known expertise to identify and evaluate the alternative opportunities available for the company. At the moment, Ampliphi will not disclose the timelines for the explored strategic alternatives until the project matures.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ampliphi Biosciences Corp (NYSEMKT:APHB) has proclaimed the positive feedback they got from the U.S. based Food and Drug Administration (FDA) on their second phase of [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":38677,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12535,12534,12537,12411,12536],"stock_ticker":[],"class_list":["post-38670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-ampliphi-biosciences-corp","tag-ampliphi-biosciences-corp-nysemktaphb","tag-aphb","tag-nysemkt","tag-nysemktaphb","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Ampliphi Biosciences Corp (NYSEMKT:APHB) has proclaimed the positive feedback they got from the U.S. based Food and Drug Administration (FDA) on their second phase of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-20T11:15:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lisa Ray\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lisa Ray\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\"},\"author\":{\"name\":\"Lisa Ray\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\"},\"headline\":\"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal\",\"datePublished\":\"2017-04-20T11:15:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\"},\"wordCount\":374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg\",\"keywords\":[\"Ampliphi Biosciences Corp\",\"Ampliphi Biosciences Corp (NYSEMKT:APHB)\",\"APHB\",\"NYSEMKT\",\"NYSEMKT:APHB\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\",\"name\":\"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg\",\"datePublished\":\"2017-04-20T11:15:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\",\"name\":\"Lisa Ray\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"caption\":\"Lisa Ray\"},\"description\":\"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670","og_locale":"en_US","og_type":"article","og_title":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR","og_description":"Ampliphi Biosciences Corp (NYSEMKT:APHB) has proclaimed the positive feedback they got from the U.S. based Food and Drug Administration (FDA) on their second phase of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-04-20T11:15:14+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg","type":"image\/jpeg"}],"author":"Lisa Ray","twitter_misc":{"Written by":"Lisa Ray","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670"},"author":{"name":"Lisa Ray","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c"},"headline":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal","datePublished":"2017-04-20T11:15:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670"},"wordCount":374,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg","keywords":["Ampliphi Biosciences Corp","Ampliphi Biosciences Corp (NYSEMKT:APHB)","APHB","NYSEMKT","NYSEMKT:APHB"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670","url":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670","name":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg","datePublished":"2017-04-20T11:15:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38676-images__9_.jpeg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ampliphi-biosciences-corp-nysemktaphb-gets-affirmative-response-from-fda-on-phase-2-development-proposal-38670#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Ampliphi Biosciences Corp (NYSEMKT:APHB) Gets Affirmative Response From FDA On Phase 2 Development Proposal"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c","name":"Lisa Ray","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","caption":"Lisa Ray"},"description":"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/38670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=38670"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/38670\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/38677"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=38670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=38670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=38670"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=38670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}